Jérôme Paillassa1, Elsa Maitre2, Xavier Troussard3. 1. Service Des Maladies du Sang, CHU d'Angers, Angers, France. 2. Hématologie, CHU de Caen Basse Normandie, Avenue Côte de Nacre, 14033, Caen Cedex, France. 3. Hématologie, CHU de Caen Basse Normandie, Avenue Côte de Nacre, 14033, Caen Cedex, France. troussard-x@chu-caen.fr.
Abstract
PURPOSE OF REVIEW: This article aims to bring an update on the recent discoveries in hairy cell leukemia (HCL), especially findings in pathophysiology and therapeutic advances. RECENT FINDINGS: Major discoveries have been made in genetics and epigenetics of HCL. Moreover, the importance of several signaling pathways and tumor microenvironment has been recently highlighted. These findings led to the development of new targeted therapies which have shown interesting results in recent clinical trials. HCL is a chronic B-cell lymphoproliferative disorder. Most patients respond to purine nucleoside analogs (PNA) like cladribine or pentostatin. However, relapses are frequent and the disease often becomes less sensitive to chemotherapy. Recent discoveries in pathophysiology, like the presence of the V600E mutation of the B-raf proto-oncogene (BRAF) gene and the importance of the B-cell receptor (BCR) pathway, led to the development of new drugs for relapsed/refractory (R/R) HCL patients. The variant-type of HCL (HCL-V) is usually less sensitive to PNA. Chemo-immunotherapy using PNA and rituximab (R), BRAF, MEK, or Bruton Tyrosine Kinase (BTK) inhibitors may be used. Good results were recently published and achieved with moxetumomab pasudotox (Moxe), an anti-CD22 immunoconjugate. In this review, we will present an update on HCL and HCL-V, focusing on pathophysiology and recent therapeutic advances.
PURPOSE OF REVIEW: This article aims to bring an update on the recent discoveries in hairy cell leukemia (HCL), especially findings in pathophysiology and therapeutic advances. RECENT FINDINGS: Major discoveries have been made in genetics and epigenetics of HCL. Moreover, the importance of several signaling pathways and tumor microenvironment has been recently highlighted. These findings led to the development of new targeted therapies which have shown interesting results in recent clinical trials. HCL is a chronic B-cell lymphoproliferative disorder. Most patients respond to purine nucleoside analogs (PNA) like cladribine or pentostatin. However, relapses are frequent and the disease often becomes less sensitive to chemotherapy. Recent discoveries in pathophysiology, like the presence of the V600E mutation of the B-raf proto-oncogene (BRAF) gene and the importance of the B-cell receptor (BCR) pathway, led to the development of new drugs for relapsed/refractory (R/R) HCL patients. The variant-type of HCL (HCL-V) is usually less sensitive to PNA. Chemo-immunotherapy using PNA and rituximab (R), BRAF, MEK, or Bruton Tyrosine Kinase (BTK) inhibitors may be used. Good results were recently published and achieved with moxetumomab pasudotox (Moxe), an anti-CD22 immunoconjugate. In this review, we will present an update on HCL and HCL-V, focusing on pathophysiology and recent therapeutic advances.
Authors: Constantin A Dasanu; Magali Van den Bergh; Donna Pepito; Juliana Alvarez Argote Journal: Curr Med Res Opin Date: 2014-10-17 Impact factor: 2.580
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: James R Cerhan; Anne Kricker; Ora Paltiel; Christopher R Flowers; Sophia S Wang; Alain Monnereau; Aaron Blair; Luigino Dal Maso; Eleanor V Kane; Alexandra Nieters; James M Foran; Lucia Miligi; Jacqueline Clavel; Leslie Bernstein; Nathaniel Rothman; Susan L Slager; Joshua N Sampson; Lindsay M Morton; Christine F Skibola Journal: J Natl Cancer Inst Monogr Date: 2014-08
Authors: Lauren R Teras; Carol E DeSantis; James R Cerhan; Lindsay M Morton; Ahmedin Jemal; Christopher R Flowers Journal: CA Cancer J Clin Date: 2016-09-12 Impact factor: 508.702